骨折复位影响医疗保险经济学(FRAME):骨质疏松症诊断与治疗增加的影响

Fracture Reduction Affects Medicare Economics (FRAME): impact of increased osteoporosis diagnosis and treatment.

作者信息

King Alison B, Saag K G, Burge R T, Pisu M, Goel N

机构信息

Public Policy, Procter & Gamble Pharmaceuticals, P.O. Box 191, Norwich, NY 13815, USA.

出版信息

Osteoporos Int. 2005 Dec;16(12):1545-57. doi: 10.1007/s00198-005-1869-5. Epub 2005 Jun 8.

Abstract

Osteoporosis is a common, debilitating disease affecting US Medicare beneficiaries, yet diagnosis and treatment lag behind medical advances. We estimated the cost of fractures to the Medicare program and the impact of increasing osteoporosis diagnosis and treatment. A Markov model was used to predict fracture incidence and costs in postmenopausal women aged 65 years and older, over 3 years (2001-2003). Only 1.80 million women were estimated to receive a Medicare-reimbursed bone mineral density (BMD) test in 2001. We evaluated the budget impact of testing an additional 1 million women from Medicare and patient perspectives. These women were stratified into high-risk (osteoporotic with prevalent vertebral fracture) and moderate-risk (without prevalent vertebral fracture) groups. During 2001-2003, an estimated 2.39 million fractures occurred among the 5.11 million women aged 65+ with osteoporosis, at a cost to Medicare of 12.96 billion dollars. We projected that BMD testing of an additional 1 million women in 2001 would result in treatment of 440,000 new patients with a bone-specific medication, preventing over 35,000 fractures over the 3 years. The decrease in fractures would produce a net discounted savings to the Medicare budget of 77.86 million dollars. Medicare's hospital inpatient cost would decrease by 115.41 million dollars and long-term care cost by 43.51 million dollars, more than offsetting incremental outpatient cost of 81.07 million dollars. Patients would benefit from fracture avoidance, but their out-of-pocket medical costs would increase by 63.49 million dollars during 2001-2003, or 1,771 dollars per fracture avoided. Sensitivity analyses showed that savings to the Medicare program varied in proportion to the unit cost of fractures, fracture risk of the populations tested, treatment rate, and adherence to therapy. Increased osteoporosis diagnosis may produce savings for the Medicare program if interventions are targeted to women at elevated risk for fracture and may be budget neutral if all older women are screened.

摘要

骨质疏松症是一种常见的、使人衰弱的疾病,影响着美国医疗保险受益人,但诊断和治疗却落后于医学进展。我们估算了骨折给医疗保险计划带来的成本以及增加骨质疏松症诊断和治疗的影响。采用马尔可夫模型预测65岁及以上绝经后女性在3年(2001 - 2003年)期间的骨折发生率和成本。2001年估计只有180万女性接受了医疗保险报销的骨密度(BMD)检测。我们从医疗保险和患者的角度评估了再检测100万女性的预算影响。这些女性被分为高风险组(患有椎体骨折的骨质疏松症患者)和中度风险组(无椎体骨折)。在2001 - 2003年期间,估计511万65岁及以上患有骨质疏松症的女性中发生了239万例骨折,医疗保险为此支付了129.6亿美元。我们预计2001年再检测100万女性进行骨密度检测将使44万新患者接受针对骨骼的药物治疗,在3年内预防超过35000例骨折。骨折数量的减少将为医疗保险预算带来净贴现节省7786万美元。医疗保险的医院住院费用将减少1.1541亿美元,长期护理费用将减少4351万美元,超过抵消增加的门诊费用8107万美元。患者将从避免骨折中受益,但在2001 - 2003年期间他们的自付医疗费用将增加6349万美元,即每避免一例骨折增加1771美元。敏感性分析表明,医疗保险计划的节省与骨折的单位成本、检测人群的骨折风险、治疗率以及治疗依从性成比例变化。如果干预措施针对骨折风险较高的女性,增加骨质疏松症诊断可能为医疗保险计划节省费用;如果对所有老年女性进行筛查,可能在预算上保持平衡。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索